Fiduciary Trust Co. lessened its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 2.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 79,849 shares of the medical research company’s stock after selling 2,405 shares during the quarter. Fiduciary Trust Co.’s holdings in Amgen were worth $14,888,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Shelton Capital Management lifted its stake in shares of Amgen by 82.7% in the first quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock worth $17,883,000 after acquiring an additional 49,354 shares in the last quarter. Welch Group LLC acquired a new position in shares of Amgen in the second quarter worth about $639,000. DekaBank Deutsche Girozentrale lifted its stake in shares of Amgen by 2.8% in the second quarter. DekaBank Deutsche Girozentrale now owns 883,579 shares of the medical research company’s stock worth $152,927,000 after acquiring an additional 24,219 shares in the last quarter. Pacer Advisors Inc. lifted its stake in shares of Amgen by 10.3% in the second quarter. Pacer Advisors Inc. now owns 25,378 shares of the medical research company’s stock worth $4,371,000 after acquiring an additional 2,362 shares in the last quarter. Finally, Wesbanco Bank Inc. raised its stake in Amgen by 6.5% during the second quarter. Wesbanco Bank Inc. now owns 106,792 shares of the medical research company’s stock valued at $18,393,000 after buying an additional 6,492 shares in the last quarter. Institutional investors own 78.46% of the company’s stock.

In related news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $176.83, for a total value of $269,665.75. Following the completion of the transaction, the executive vice president now directly owns 56,106 shares of the company’s stock, valued at approximately $9,921,223.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. Insiders have sold 7,050 shares of company stock valued at $1,225,765 over the last ninety days. Corporate insiders own 0.19% of the company’s stock.

Several analysts have issued reports on AMGN shares. BMO Capital Markets restated a “market perform” rating and set a $198.00 price objective on shares of Amgen in a research note on Thursday, October 26th. Mizuho restated a “buy” rating and set a $198.00 price objective (up previously from $183.00) on shares of Amgen in a research note on Thursday, September 28th. Zacks Investment Research cut Amgen from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. BidaskClub upgraded Amgen from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 2nd. Finally, Morgan Stanley restated an “overweight” rating and set a $196.00 price objective (up previously from $189.00) on shares of Amgen in a research note on Friday, October 6th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $190.15.

Amgen, Inc. (NASDAQ:AMGN) opened at $180.60 on Tuesday. The company has a market capitalization of $131,100.00, a P/E ratio of 16.31, a PEG ratio of 2.60 and a beta of 1.36. Amgen, Inc. has a fifty-two week low of $150.38 and a fifty-two week high of $191.10. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.77 billion during the quarter, compared to analyst estimates of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The business’s revenue was down .7% compared to the same quarter last year. During the same period in the prior year, the company earned $3.02 earnings per share. sell-side analysts predict that Amgen, Inc. will post 12.71 EPS for the current fiscal year.

Amgen declared that its Board of Directors has initiated a share repurchase program on Wednesday, October 25th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be issued a dividend of $1.32 per share. The ex-dividend date is Wednesday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 annualized dividend and a dividend yield of 2.92%. Amgen’s dividend payout ratio is 41.55%.

COPYRIGHT VIOLATION NOTICE: “Fiduciary Trust Co. Sells 2,405 Shares of Amgen, Inc. (AMGN)” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/fiduciary-trust-co-sells-2405-shares-of-amgen-inc-amgn/1799347.html.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.